Abstract 426P
Background
The support for caregivers (CG) of patients with cancer is an essential factor for maintaining the safety and continuity of palliative chemotherapy. Because of insufficient knowledge regarding their QOL, there are no durable strategies for supporting CGs during the treatment.
Methods
We aimed to assess the QOL of the CGs of patients with cancer undergoing palliative chemotherapy. This single-institution, prospective, observational study was approvedby the institutional review board of Ina Central Hospital on July 20th 2016. Total 102 patients undergoing palliative chemotherapy (64 male and 38 female patients; mean age 68.8 years) and their CGs (30 maleand 72 female; mean age 64.3 years) were included. The primary lesions in the patients were pancreatic in 30, colorectal in 21, stomach or duodenal in 21, oesophageal in 18, and biliary in 12. We used EORTC QL-C-30 to assess the QOL of patients and CGs at the beginning of the first-line chemotherapy. A total of 29 of 102 pairs of patients and CGs were assessed at the beginning of the first and second-line chemotherapies. According to a formula incorporating measures of clinical symptoms and comprehensive scales of physical function (PF), role function (RF), emotional function (EF), cognitive function (CF), and social function. In addition, a summary score (SS) and a global health scale (GHS) on QOL were computed using comprehensive scales.
Results
All the parameters assessed in CGs yielded higher values than those for patients; however, EF and CF did not show significant differences between patients and CGs. Among longitudinal observed pairs, discrepancies in GHS and SS between patients and CGs were identified in 38 % and 34%, respectively. Those CGs who did not demonstrate an improvement in GHS compared with those who showed an improvement in this parameter had lower PF and RF values at the beginning of the treatment.
Conclusions
Even at the beginning of the treatment, the CGs of patients with cancer undergoing palliative chemotherapy showed impairment in daily QOL. In addition, emotional and cognitive functions were impaired as much as patients. CGs with physical difficulty and role function impairment in family should be monitored for worsening of their QOL during the course of treatment.
Clinical trial identification
Editorial acknowledgement
This has been edited for English language, grammar, punctuation, and spelling by Enago, the editing brand of Crimson Interactive Pvt. Ltd under Normal Editing.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
490P - Outcomes of sequential epidermal growth factor receptor tyrosine (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced non-small cell lung carcinoma (NSCLC)- a real-world institutional experience
Presenter: Yvonne Ang
Session: Poster display session
Resources:
Abstract
498P - An observational retrospective study to evaluate the incidence of acquired EGFR T790M resistance in NSCLC patients with EGFR mutation following progression after at least one prior EGFR TKI treatment in Taiwan: ARISE study
Presenter: Shang-gin Wu
Session: Poster display session
Resources:
Abstract
501P - Clinical characteristics and efficacy in non-small cell lung cancer patients with EGFR exon 20 insertion and EGFR amplification
Presenter: Xin Gao
Session: Poster display session
Resources:
Abstract
502P - Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced non-small cell lung cancer with uncommon mutations: A multicenter observational study
Presenter: Masaki Kanazu
Session: Poster display session
Resources:
Abstract
482P - Interim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo De Marinis
Session: Poster display session
Resources:
Abstract
483P - A phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: A biomarker analysis
Presenter: Rafael Rosell
Session: Poster display session
Resources:
Abstract
484P - Activity of afatinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC and baseline brain metastases: Pooled analysis of three large phase IIIb trials
Presenter: Maya Gottfried
Session: Poster display session
Resources:
Abstract
491P - Clinical outcomes of leptomeningeal metastases in EGFR-mutant lung adenocarcinoma
Presenter: Chia-I Shen
Session: Poster display session
Resources:
Abstract
510P - Paclitaxel as continuation maintenance therapy in patients with advanced non-small cell lung cancer
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract
496P - Higher osimertinib introduction rate achieved by multiple repeated re-biopsy after acquired resistance to first/second generation EGFR-TKIs
Presenter: Taira Ninomaru
Session: Poster display session
Resources:
Abstract